@FiercePharma: Another J&J recall, another hit to J&J's image. Article | Follow @FiercePharma
> Amgen will sell its Fremont, California, research and manufacturing operations to Boehringer Ingelheim for an undisclosed price; 360 employees currently work there. Report
> Biomarkers finally get respect, but challenges remain. Article
> Israeli researcher finds blood cancer biomarkers. Item
> Pfizer and Eisai's Aricept, Shire's Reminyl and Novartis' Exelon won backing from the U.K. cost-effectiveness watchdog for expanded use in patients with mild or moderate Alzheimer's disease, in addition to more severe illness. News
> There is not enough evidence to recommend widespread use of statins like Pfizer's Lipitor or AstraZeneca's Crestor in people with no previous history of heart disease, scientists said in a new review. Story
> Mylan shares jumped in trading after the generic drugmaker said it received approval to make three doses of a generic version of Bayer's Precose tablets, which are used to treat diabetes. Mylan release | Item
> GlaxoSmithKline has started a pivotal study testing intravenous zanamivir, approved in inhaled form as Relenza, against Roche's best-selling pill Tamiflu as a treatment for patients hospitalised with influenza. Article
> J&J job ads emphasize change in focus. News
> San Diego's Cadence Pharmaceuticals said that it has launched Ofirmev, the first intravenous formulation of acetaminophen, in the U.S.; it won FDA approval in November. Report
> Colin Mackenzie has been appointed the new president of GlaxoSmithKline Consumer Healthcare North America, succeeding Roger Scarlett-Smith, who will become president of GSK Consumer Healthcare Europe. News
> DNA overexpression might be cancer biomarker. Report
> Canada risks losing out on the next wave of lucrative pharmaceutical investment and jobs unless it matches tougher patent protection for drugmakers in the U.S. and Europe, says a new report for the Canadian Chamber of Commerce. Story
> Biomarkers are biting on scientific fishing expedition. Article
> Takeda, Zinfandel double-team Alzheimer's biomarker. Item
Biotech News
@FierceBiotech: Feds' $1B antiterror drug development program yields little. News | Follow @FierceBiotech
@JohnCFierce: Ariad shares shot up 36% on this morning's sarcoma data. Three weeks isn't much time, but deadly cancers have their own metric for success. | Follow @JohnCFierce
> Pfizer, Theraclone ink $632 R&D deal for cancer, infectious disease. News
> Roche, Plexxikon melanoma drug extends patients' lives. Article
> pSivida raises $11M in RDO. Story
> Ironwood, Protagonist ink peptide discovery deal. Report
Drug Delivery News
> Lincoln Pharma gets patent for nasal delivery of anti-vomiting drug. Story
> Hot gold nanoparticles can cook cancer cells. Report
> Spider silk protein could make terrific delivery device. Item
> Cancer cells hit with a 'Big Mac' attack. Article
> A magnet car for your GI tract could deliver meds. Story
Medical Device News
> PwC: Emerging med tech markets catching up to U.S. Item
> Smiths Group rejects $3.9B offer for medical unit. Story
> S&N: We're not in merger talks. Report
> Report: iWalk raises $15M. News
> Obama: FDA med device changes coming today. Article
> Tornier releases IPO terms. Report
> Oval Medical raises cash, reports positive study results. News
And Finally... Two online communities for doctors have launched a strategic alliance to help them expand their reach internationally, aiming for business from the pharma industry. Report